- Home
- SLRC vs PRTA Comparison
SLRC vs PRTA Comparison
Compare SLRC & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRC
- PRTA
- Stock Information
- Founded
- SLRC 2007
- PRTA 2012
- Country
- SLRC United States
- PRTA Ireland
- Employees
- SLRC N/A
- PRTA N/A
- Industry
- SLRC Finance/Investors Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- SLRC Finance
- PRTA Health Care
- Exchange
- SLRC Nasdaq
- PRTA Nasdaq
- Market Cap
- SLRC 895.2M
- PRTA 809.8M
- IPO Year
- SLRC 2010
- PRTA N/A
- Fundamental
- Price
- SLRC $16.89
- PRTA $14.07
- Analyst Decision
- SLRC Hold
- PRTA Buy
- Analyst Count
- SLRC 5
- PRTA 9
- Target Price
- SLRC $15.85
- PRTA $54.57
- AVG Volume (30 Days)
- SLRC 217.9K
- PRTA 415.9K
- Earning Date
- SLRC 05-07-2025
- PRTA 05-07-2025
- Dividend Yield
- SLRC 9.71%
- PRTA N/A
- EPS Growth
- SLRC 25.36
- PRTA N/A
- EPS
- SLRC 1.76
- PRTA N/A
- Revenue
- SLRC $232,431,000.00
- PRTA $135,157,000.00
- Revenue This Year
- SLRC N/A
- PRTA N/A
- Revenue Next Year
- SLRC N/A
- PRTA $131.75
- P/E Ratio
- SLRC $9.62
- PRTA N/A
- Revenue Growth
- SLRC 1.36
- PRTA 47.92
- 52 Week Low
- SLRC $14.41
- PRTA $11.70
- 52 Week High
- SLRC $17.94
- PRTA $28.53
- Technical
- Relative Strength Index (RSI)
- SLRC 40.04
- PRTA 45.57
- Support Level
- SLRC $17.14
- PRTA $13.41
- Resistance Level
- SLRC $17.94
- PRTA $15.63
- Average True Range (ATR)
- SLRC 0.38
- PRTA 1.05
- MACD
- SLRC -0.09
- PRTA -0.13
- Stochastic Oscillator
- SLRC 9.48
- PRTA 24.14
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).